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I N T R O D U C T I O N
Modern understanding of synaptic ion channels began 
with the isolation (Karlin and Cowburn, 1973) and sub-
sequent cloning of nicotinic acetylcholine (ACh) recep-
tors (nAChRs) (Numa et al., 1983). Based on the presence 
of primary binding site elements, including a pair of 
vicinal cysteines, 10 different nAChR subunits have been 
identified in vertebrates as  subunits (1–10). Non– 
subunits, which demonstrably contain the required ele-
ments for forming the complementary surface of an ago-
nist binding site, are , , and  in muscle-type receptors 
and 2 and 4 in neuronal receptors.
The nAChR ligand binding domain is formed by the 
interface of two protein subunits; the primary surface is 
formed by an  subunit, which contains several other 
key elements in addition to the adjacent cysteines of a 
subdomain identified as the C-loop (Sine, 2002). The 
distinction between  and non– subunits relates to a 
key dichotomy in several of the subfamilies of Cys-loop 
receptors between types that function as pentamers of 
an identical  subunit (homomeric receptors) and those 
that require both  and non– subunits in each penta-
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meric complex (heteromeric receptors). In the subfam-
ily of mammalian nAChRs, homomeric receptors, such 
as 7, are considered ancestral to heteromeric combi-
nations and can be activated by both ACh and the 
precursor/metabolite, choline (Papke et al., 1996). Sub-
units like 7 are able to contribute to five agonist bind-
ing sites at both primary and complementary interface 
surfaces (Palma et al., 1996), whereas heteromeric re-
ceptors, which require specialized non– subunits for 
the complementary side of the binding site, are limited 
to two agonist binding sites.
ACh is a nearly perfect molecule for fast and transient 
synaptic signaling at sites like the neuromuscular junc-
tion, as it is rapidly released and efficiently hydrolyzed. 
However, nicotinic signaling appears to be fundamen-
tally different in the brain, where rhythmic ACh release 
occurs diffusely, rather than at focused synaptic sites, 
and a primary role of nAChRs in the brain is to modu-
late neuronal excitability and release of other neuro-
transmitters (Descarries et al., 1997; Dani and Bertrand, 
2007). As a result of esterases, extracellular concentra-
tions of diffusely released ACh are expected to be low. 
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nated. Modification of 7L119C mutants by the sulfhydryl reagent 2-aminoethyl methanethiosulfonate (MTSEA) 
reduces responses to acetylcholine (ACh) by more than 97%, whereas corresponding mutations in muscle-type re-
ceptors produce effects that depend on the specific subunits mutated and ACh concentration. We coexpressed 
7L119C subunits with pseudo wild-type 7C116S subunits, as well as ACh-insensitive 7Y188F subunits with wild-
type 7 subunits in Xenopus laevis oocytes using varying ratios of cRNA. When mutant 7 cRNA was coinjected at a 
5:1 ratio with wild-type cRNA, net charge responses to 300 µM ACh were retained by 7L119C-containing mutants 
after MTSEA modification and by the ACh-insensitive Y188F-containing mutants, even though the expected num-
ber of ACh-sensitive wild-type binding sites would on average be fewer than two per receptor. Responses of muscle-
type receptors with one MTSEA-sensitive subunit were reduced at low ACh concentrations, but much less of an 
effect was observed when ACh concentrations were high (1 mM), indicating that saturation of a single binding site 
with agonist can evoke strong activation of nicotinic ACh receptors. Single-channel patch clamp analysis revealed 
that the burst durations of fetal wild-type and 11L121C receptors were equivalent until the 11L121C 
mutants were exposed to MTSEA, after which the majority (81%) of bursts were brief (≤2 ms). The longest dura-
tion events of the receptors modified at only one binding site were similar to the long bursts of native receptors tra-
ditionally associated with the activation of receptors with two sites containing bound agonists.
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Expression in Xenopus oocytes
Mature (>9 cm) female Xenopus African frogs (Nasco) were used 
as the source of oocytes. The frogs were maintained in the Animal 
Care Services facility of the University of Florida, which is fully   
accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care, and all procedures were approved by 
the University of Florida Institutional Animal Care and Use Com-
mittee. Before surgery, frogs were anesthetized by placing each 
animal in a 1.5-g/liter solution of 3-aminobenzoic acid ethyl ester 
(Sigma-Aldrich) for 30 min. Oocytes were removed from an ab-
dominal incision.
To  remove  the  follicular  cell  layer,  harvested  oocytes  were 
treated with 1.25 mg/ml collagenase (Worthington Biochemical 
Corporation) for 2 h at room temperature in calcium-free Barth’s 
solution (88 mM NaCl, 1 mM KCl, 2.38 mM NaHCO3, 0.82 mM 
MgSO4, 15 mM HEPES, pH 7.6, and 12 g/liter tetracycline).   
Subsequently, stage 5 oocytes were isolated and injected with   
50 nl (5–20 ng) each of the appropriate subunit cRNAs. Muscle-
type receptor cRNAs were injected in the ratio of 2:1:1:1 or 
1. Recordings were made 1–7 d after injection. Although the abso-
lute magnitude of the evoked current responses increased over 
time, the normalized values of the experimental responses did 
not vary significantly over time.
Cell culture and transient transfection of BOSC 23 cells
BOSC 23 cells obtained from American Type Culture Collection 
were cultured at 37°C, 5% CO2 in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum in the absence of antibiotics. 
Cells were discarded and fresh cells were thawed once 35 passages 
were reached. Cells were transiently transfected using Fugene 6 
(Roche) according to the manufacturer’s instructions. 1 d before 
transfection, cells were plated onto 12-mm glass coverslips (Thermo 
Fischer Scientific) coated with poly-d-lysine (Sigma-Aldrich). 1 µg 
of  mouse  fetal  muscle–type  receptor  cDNA  (2:1:1:1)  in 
pRBG4 with 0.8 µg of the cDNA encoding red fﾭlﾭuorescent protein 
in pDsRed (Takara Bio Inc.) was added to each 35-mm dish con-
taining cells and coverslips. Experiments were performed 48–72 h 
after  transfection.  The  red  fﾭlﾭuorescent  protein  was  used  as  a 
marker to identify successfully transfected cells.
Chemicals
2-aminoethyl methanethiosulfonate (MTSEA) was purchased 
from  Toronto  Research  Chemicals  Inc.  All  other  chemicals   
for electrophysiology were obtained from Sigma-Aldrich. Fresh 
ACh and MTSEA stock solutions were made each day of experi-
mentation. MTSEA stock solutions were made in water, kept on 
ice, and diluted just before experiments. 3-(4-hydroxy, 2-methoxy-
benzylidene) anabaseine (4OH-GTS-21) was provided by Taiho 
Pharmaceutical Co.
Two-electrode voltage clamp electrophysiology
Experiments were conducted using OpusXpress 6000A (Molecu-
lar Devices) (Stokes et al., 2004). OpusXpress is an integrated sys-
tem that provides automated impalement and voltage clamp of 
up to eight oocytes in parallel. Oocytes were automatically per-
fused with bath solution, and agonist solutions were delivered 
from a 96-well plate. Both the voltage and current electrodes were 
filled with 3 M KCl. The agonist solutions were applied via dispos-
able tips, which eliminated any possibility of cross-contamination. 
Drug applications alternated between ACh controls and experi-
mental applications. Flow rates were set at 2 ml/min for experi-
ments with 7 receptors and at 4 ml/min for other subtypes. 
Oocytes were voltage clamped at a holding potential of 60 mV. 
Data were collected at 50 Hz and filtered at 20 Hz. Unless other-
wise indicated, drug applications were 12 s in duration followed 
by 181-s washout periods with 7 receptors and 8 s with 241-s 
washout periods for other subtypes.
Although choline is ubiquitous in the brain and body, 
concentrations are still well below the EC50 for acute   
activation of 7 (Papke and Porter Papke, 2002), even 
under conditions of trauma when choline concentra-
tions reach 100 µM (Jope and Gu, 1991; Scremin and 
Jenden, 1991). In addition, responses of 7 receptors to 
high ACh concentrations are very limited (Papke et al., 
2000; Papke and Porter Papke, 2002), which raises the 
question of whether 7 nAChR may function effectively 
under conditions of low fractional occupancy of the ago-
nist binding sites. Single-channel studies of muscle-type 
nAChR have associated brief openings observed at low 
agonist concentrations with mono-liganded receptors 
(Colquhoun and Sakmann, 1981, 1985; Takeda and 
Trautmann, 1984; Labarca et al., 1985), supporting the hy-
pothesis that the brief openings characteristic of 7 may 
also arise from the binding of single agonist molecules.
In  this  paper,  we  investigate  the  functional  signifi-
cance of the multiple agonist binding sites in hetero-
meric muscle-type and homomeric 7 forms of nAChR 
using the L119C mutation (7 numbering), which is lo-
cated on the complementary face of the agonist binding 
site across from the C-loop (see Fig. 1 A), together with 
sulfhydryl modification at that site to achieve varying 
levels of conditional binding site modification (Papke 
et al., 2011). We also use ACh-insensitive 7Y188F sub-
units (Horenstein et al., 2007) coexpressed with wild-type 
7 subunits in different ratios. Our data are consistent 
with previous reports that heteromeric muscle-type recep-
tors and homomeric Cys-loop receptors can activate with 
levels of submaximal agonist occupancy (Jackson, 1984, 
1986;  Colquhoun  and  Sakmann,  1985;  Amin  and   
Weiss, 1996; Mott et al., 2001; Beato et al., 2004; Rayes   
et al., 2009; Jha and Auerbach, 2010). Our data offer 
the additional insight that strong activation of muscle-
type and 7 nAChR may be achieved under conditions 
of agonist saturation at individual binding sites.
M AT E R I A L S   A N D   M E T H O D S
nAChR clones and mutants
Mouse muscle nAChR 1, 1, , and  clones used for receptor 
expression in Xenopus laevis oocytes were obtained from J. Boulter 
(University of California, Las Angeles, Los Angeles, CA), and the 
mouse  clone was provided by P. Gardner (University of Massa-
chusetts  Medical  School,  Worcester,  MA).  The  mouse  muscle 
cDNA clones in pRBG4 used for transfection of BOSC 23 cells 
were  obtained  from  S.  Sine  (Mayo  Clinic,  Rochester,  MN).   
The human 7 clones were provided by J. Lindstrom (University 
of Pennsylvania, Philadelphia, PA). Mutations to cDNA clones 
were introduced using the QuikChange kit from Agilent Technol-
ogies according to the manufacturer’s instructions. The muta-
tions were confirmed with automated fﾭlﾭuorescent sequencing.
Preparation of RNA for injection into Xenopus oocytes
After linearization and purification of cloned cDNAs, cRNA tran-
scripts were prepared in vitro using the appropriate mMessage 
mMachine kit (Invitrogen).  Williams et al. 371
recording pipette. To maintain undisturbed laminar fﾭlﾭow from 
the application pipette and minimize solution mixing, external 
saline solution was continuously perfused through the recording 
chamber (Warner Instruments) at a rate of 6 ml/min, and the ap-
plication pipette was positioned such that streams fﾭlﾭowing from it 
would directly enter the aspiration port of the chamber. In addi-
tion, the tip of the application pipette was kept free of dirt and/or 
cell debris by periodic cleaning in a hydrochloric acid solution. 
All solutions were degassed under vacuum and passed through a 
0.2-µm filter to reduce the probability of particles/air bubbles ob-
structing solution fﾭlﾭow and/or damaging the outside-out patch.
Once a stable outside-out patch was obtained and the applica-
tion and recording pipettes were aligned, the stream of external 
solution exiting channel 1 was turned on, followed by the 1-mM 
ACh stream in channel 2. The piezoelectric stepper was then used 
to move the 1-mM ACh stream over the patch for the pre-MTSEA 
treatment ACh response. 30 s before termination of the first ACh 
application, the fﾭlﾭow exiting channel 1 was replaced with the 5-mM 
MTSEA solution. MTSEA was then applied to the patch for 60 s, 
after which the 1-mM ACh stream was moved back over the 
patch for the post-MTSEA treatment ACh response. Any time 
MTSEA entered the bath chamber, whether the patch survived 
the entire protocol or not, the chamber was completely emptied 
and thoroughly rinsed, the application pipette was fﾭlﾭushed for 
at least 5 min with external solution that was collected in a bea-
ker separate from the bath chamber, and the coverslip of cells 
was  replaced.  Patches  were  not  treated  with  MTSEA  for  the   
experiments in which 10 nM ACh was applied to 11L121C-
mutant receptors.
All patch clamp recordings were processed, idealized, and ana-
lyzed with Clampfit 10 (Molecular Devices). Before any analysis, 
each recording was additionally low-pass filtered to 5 kHz with a 
software filter simulating an eight-pole Bessel filter, corrected for 
baseline drift, and any recorded artifacts or spurious noise was re-
moved. The 5-kHz filter frequency was selected as a compromise 
between reliable event detection and total bandwidth. A resolu-
tion limit of 1.3 filter rise time was set at 86 µsec and imposed 
on all recordings (Mortensen and Smart, 2007).
Absolute Popen (NPopen) values were used as the primary mea-
sure of response to ACh for the outside-out patch clamp experi-
ments in a manner analogous to the net charge measurements 
made from responses by receptors expressed in Xenopus oocytes. 
The NPopen value was computed for an entire response to ACh,   
including the nonstationary phase of activation by
  NPopen = ∫
1
0 iD
I t dt
D
( ) ,  
where I is the recorded current relative to baseline, t is time, i is 
the mean single-channel amplitude, and D is the duration of the 
ACh application (Jackson, 1998). No attempt was made to esti-
mate Popen for an individual channel because the total number of 
activatible channels in a patch could not be known with any de-
gree of certainty, and because each patch served as its own con-
trol. Therefore, no kinetic information relating to a single channel 
is intended by the NPopen measurement.
Recordings containing minimal simultaneous channel open-
ings were selected for half-amplitude idealization and analysis of 
single-channel burst durations. When simultaneous channel open-
ings occurred, segments of data containing single-channel activity 
were selected so that nonconducting fﾭlﾭanking regions were ≥50 ms. 
Apparent subconductances occurred occasionally but were ig-
nored because they were not obvious in all traces and because 
they appeared to occur independently of MTSEA treatment. Data 
from at least four individual patches from each condition were 
pooled together to obtain sufficient numbers of events for analysis. 
Each oocyte received two initial control applications of ACh, an 
experimental drug application, and then a follow-up control ap-
plication of ACh. The control ACh concentrations were 300 µM 
for 7 and 30 µM for muscle subunit combinations. The peak am-
plitude and the net charge (Papke and Porter Papke, 2002) of   
experimental responses were calculated relative to the preceding 
ACh control responses to normalize the data, compensating for 
the varying levels of channel expression among the oocytes. After 
each experimental measurement, oocytes were rechallenged with 
ACh at the control concentrations. Means and standard errors 
(SEM) were calculated from the normalized responses of at least 
four oocytes for each experimental concentration. The standard 
MTSEA treatment in the oocyte experiments was 2 mM applied 
for 60 s, a treatment that appears to produce a maximal effect on 
receptors expressed in Xenopus oocytes (Wang et al., 2010).
For concentration–response relationships, data were plotted 
using Kaleidagraph 3.0.2 (Abelbeck Software), and curves were gen-
erated as the best fit of the average values to the Hill equation:
  Response  =
+
I agonist
agonist EC
n
n n
max[ ]
[ ] ( )
,
50
 
where Imax denotes the maximal response for a particular agonist/
subunit combination, and n represents the Hill coefficient. For 
the calculation of EC50 values, Imax was constrained to equal 1 and 
error estimates of the EC50 values are the standard errors of the 
parameters based on the Levenberg-Marquardt algorithm used 
for the generation of the fits (Press, 1988).
Outside-out patch clamp electrophysiology
Single-channel currents were recorded in the outside-out patch 
configuration using an Axopatch 200A amplifier (Molecular De-
vices) at room temperature. Cells were bathed in an external solu-
tion containing (in mM): 165 NaCl, 5 KCl, 2 CaCl2, 10 glucose,   
5 HEPES, and 0.001 atropine, with pH adjusted to 7.3 with NaOH. 
Patch pipettes (Sutter Instrument) were pulled to a tip diameter 
of  1–2  µm,  fire-polished  to  5–10  M,  coated  with  SigmaCote 
(Sigma-Aldrich), and filled with an internal solution containing 
(in mM): 147 CsCl, 2 MgCl2, 1 CaCl2, 10 EGTA, 10 HEPES, and   
2 ATP, with pH adjusted to 7.3 with CsOH. Recordings were low-
pass filtered to 10 kHz with the built-in amplifier filter (four-pole 
Bessel) and digitized at 100 kHz with a DigiData 1440 (Molecular 
Devices) using Clampex 10 data acquisition software (Molecular 
Devices). Multiple recordings for each experimental condition 
were obtained from several transfection and recording dates.
Rapid drug application to outside-out patches was performed 
in a similar manner as described by Franke et al. (1987) and Jonas 
(1995). Theta glass (Sutter Instrument) was pulled, scored, and 
then broken by hand to create an application pipette with a diam-
eter of 130 µM (septum thickness, 10 µM). The application pi-
pette was mounted to a Burleigh piezoelectric stepper (EXFO). 
The signal sent by Clampex 10 (Molecular Devices) to the piezo-
electric stepper was conditioned by an RC circuit ( = 2 ms) to re-
duce oscillations and avoid damage to the crystal (Kabakov and 
Papke, 1998).
Two  reservoirs  (60-ml  Monoject  syringe  bodies;  Sherwood 
Medical Company) were connected to each channel of the theta 
glass application pipette with polyethylene tubing. Channel 1 of 
the application pipette was connected to reservoirs containing 
either external saline solution or 5 mM MTSEA, and channel 2 was 
connected to reservoirs containing either 1 mM ACh or external 
saline solution. Flow rates from each reservoir and channel were 
an equivalent 8.5 cm/s. The time required to replace solution 
fﾭlﾭow in a channel was 30 s. Solution exchange times (10–90% rise 
times) were typically 0.4–0.7 ms and were routinely determined 
by movement of 50% diluted external solution over an open 372 nAChR activation with single binding sites
different from wild-type and are unaffected by the applica-
tion of MTSEA (Papke et al., 2011). A similar pseudo 
wild-type background was used in other studies that intro-
duced cysteine mutations into 7 (Barron et al., 2009).
The  L119C  mutation  was  identified  as  an  effective 
tool for the investigation of nAChR binding sites be-
cause receptors containing this mutation responded 
normally to ACh, tetramethyl ammonium, quinucli-
dine, and 4OH-GTS-21 until treated with MTSEA or any 
of the three other cationic sulfhydryl reagents applied, 
after which agonist-induced responses were nearly com-
pletely abolished (Papke et al., 2011). The near 100% 
reduction in response to 300 µM ACh that is typical 
when 2 mM MTSEA is applied for 60 s to 7C116S/
L119C-mutant receptors expressed in oocytes is shown 
in Fig. 1 B. The degree of inhibition is not significantly 
dependent on the ACh concentration used to evoke the 
responses.  In  the  specific  experiment  illustrated,  net 
charge responses to 300 µM ACh were reduced by 99.7 ± 
0.1%, and responses to 3 mM ACh were reduced to a 
similar extent (95.9 ± 2.0%; not depicted).
Effects of 7L119C ratios in mixed 7  
wild-type/mutant heteromers
We sought to test the hypothesis that 7 receptors may 
be activated, even if the receptors have a reduced number 
Burst analysis was conducted with the intention of defining groups 
of one or more apparent channel openings that arise from an 
individual channel. Apparent channel openings separated by a 
closed interval less than the defined critical duration (tcrit) of 3.4 ms 
were  called  a  burst  of  openings.  The  tcrit  value  was  calculated 
based on the equation  e   e
t / t / crit fast crit slow − − = −
τ τ 1 , which misclassi-
fies equal proportions of short and long intervals, from fit time 
constants of the closed duration histogram of non-MTSEA–treated 
11L121C receptors (Colquhoun and Sakmann, 1985, 1995). 
The tcrit value determined for wild-type 11 receptors was 
3.1 ms; small variations in tcrit values did not lead to significant 
changes in burst durations, and for consistency, the tcrit value of 
3.4 ms was applied to the wild-type recordings. The value of tcrit 
for 11L121C patches that received 10 nM ACh was defined 
as 3.8 ms by the same method.
R E S U LT S
Identification of the 7L119C mutation as a tool to study 
nAChR binding sites
The 7 receptor contains a free cysteine residue at posi-
tion 116. To prevent nonspecific modification and/or 
potential disulfide formations between the single free 
cysteine at position 116 and the introduced cysteine, we 
used a cysteine-null pseudo wild-type C116S background. 
Responses  of  pseudo  wild-type  7C116S  receptors  to 
EC50 concentrations of ACh, tetramethyl ammonium, 
quinuclidine, and 4OH-GTS-21 are not significantly 
Figure 1.  Location of the L119 residue in a homology model of 7 (Celie et al., 2004). (A) The overview at left shows an 7-7 homo-
dimer and the location of the L119 residue in relation to the C-loop in the primary face of the agonist binding site. The image on the 
right shows the proximity at increased magnification. Images were created in Deep View (Swiss-PdbViewer; Guex and Peitsch, 1997) 
from the crystal structure model of the ACh binding protein (deposited in the Protein Data Bank under accession no. 1I9B; Brejc et al., 
2001). (B) The effect of MTSEA treatment (2 mM for 60 s) on the ACh-evoked responses of oocytes expressing the 7L119C mutation 
in a cysteine-null (7C116S) background. In this experiment, peak current responses to 300 µM ACh were reduced 99.4 ± 0.2%, and 
net charge was reduced by 99.7 ± 0.1% (n = 4). Responses to 3 mM ACh were reduced to a similar extent: 97.9 ± 0.3 and 95.9 ± 2.0% for 
peak current and net charge, respectively (n = 4).  Williams et al. 373
7C116S and 7L119C mutations appeared to disrupt 
the binding of the competitive antagonist, and such ex-
periments were not possible to pursue. Comparison of 
the magnitude of non-normalized functional responses 
from oocytes to the same concentration of ACh (300 µM) 
that was injected the same day, with the same amount of 
RNA from the same harvest of oocytes, revealed equiva-
lent responses among the 7C116S/L119C, 1:1, 3:1, 
and 5:1 groups. The functional responses of the oocytes 
injected with 7C116S alone were threefold greater 
(n ≥ 5 oocytes for each group; not depicted).
Control responses to 300 µM ACh were recorded for 
each cell in the three injection sets before MTSEA treat-
ment (Fig. 2 B). After treating the oocytes with MTSEA 
(2 mM for 60 s), oocytes were tested with a range of 
of activatable binding sites. We injected Xenopus oocytes 
with RNA coding for 7C116S (pseudo wild-type) sub-
units and the MTSEA-sensitive 7C116S/L119C sub-
units in varying ratios. The possible subunit combinations 
and likely distributions of those combinations as a prob-
abilistic function of the RNA ratios, assuming equal   
expression and assembly of the wild-type and mutant 
subunits, are shown in Fig. 2 A. With the highest ratio 
(5:1) of 7C116S/L119C to 7C116S, less than 4% of 
the receptors would be predicted to have more than two 
MTSEA-insensitive binding sites, and 40% would be 
predicted to be fully MTSEA sensitive. We attempted to 
verify expression of the 7L119C-mutant subunits by 
comparison of radiolabeled -bungarotoxin (-btx) 
binding before and after MTSEA treatment. However, the 
Figure 2.  Coexpression of either L119C or Y188F with wild-type 7 subunits at varying ratios. (A) The probability for the distribution of 
mutant subunits based on RNA ratios. Each single subunit within a pentamer is either mutant or wild-type, and if we assume X = prob-
ability of being wild-type (actually 7C116S) and Y = probability of being mutant, then 1 = X + Y, and for combinations of five subunits, 
(X + Y)
n = 1. The expansion of this binomial is X
5 + 5X
4Y + 10X
3Y
2 + 10X
2Y
3 + 5XY
4 + Y
5 = 1. We assume that receptors are functionally 
equivalent regardless of the subunit positions within the pentameric structure. (B) Data traces obtained from oocytes expressing the 
7C116S/L119C MTSEA-sensitive mutant and the 7C116S cysteine-null pseudo wild-type at the ratios indicated. For each panel, the 
traces on the left are the 300-µM ACh control responses obtained before the MTSEA treatment, and the series of traces on the right 
are the responses to progressively greater concentrations of ACh obtained after the MTSEA treatment. (C) Average net charge values 
for oocytes expressing the 7C116S/L119C MTSEA-sensitive mutant and 7C116S cysteine-null pseudo wild-type at the ratios indicated 
after treatment with MTSEA, normalized to the 300-µM ACh control responses before MTSEA treatment. The open circles represent the 
300-µM ACh control data obtained before the MTSEA treatment (i.e., the values to which the posttreatment data are normalized). The 
data plotted are the means ± SEM for at least five oocytes at each of the ratios tested. See Table I for curve fit values.374 nAChR activation with single binding sites
ACh-sensitive wild-type 7 and ACh-insensitive 7Y188F 
together in Xenopus oocytes at varying ratios of RNA, 
similar to what was done with the L119C mutant (Fig. 2,   
B and C). The response evoked by 4OH-GTS-21 on 
7Y188F receptors is consistent with efficient 7Y188F 
subunit expression and assembly in oocytes (Horenstein 
et al., 2007). The mutant and wild-type subunits responded 
alike  to  300  µM  4OH-GTS-21,  but  wild-type  subunits 
were required to generate responses to 300 µM ACh. 
However, if only single subunits are required to activate 
a receptor, we hypothesized that even when 7Y188F 
was injected at a 5:1 ratio to wild-type 7, the net charge 
responses to ACh should remain relatively high because 
60% of the receptors would have at least one ACh-sensitive 
wild-type subunit. As shown in Fig. 3 B, the sensitivity of 
ACh concentrations from 30 µM to 1 mM. The averaged 
net charge data are shown in Fig. 2 C (see also Table I), 
normalized to the 300-µM ACh net charge responses 
obtained before the MTSEA treatment. The most obvi-
ous effect of the MTSEA treatment was on the responses 
to low ACh concentration in the oocytes injected with 
the highest fraction of MTSEA-sensitive mutants. In the 
control (pre-MTSEA) condition, 300 µM ACh was suffi-
cient to produce a maximal net charge response. Re-
sponses of the oocytes injected at ratios of 1:1 and 3:1 
showed  no  significant  differences  in  function  after 
MTSEA treatment (P > 0.05). Only the oocytes injected at 
the 5:1 ratio showed a significant decrease in the 300-µM 
ACh-evoked responses (P < 0.05) after MTSEA treat-
ment; however, this average decrease of 33% was less 
than the percentage of receptors predicted to be fully 
sensitive to MTSEA (40%; Fig. 2 A). Although untreated 
7 receptors (not depicted) and the treated receptors 
injected at 1:1 (Fig. 2 C) showed no increase in net 
charge  from  300  µM  to  1  mM  ACh,  the  average  re-
sponses of the 5:1 injected oocytes to 1 mM ACh in-
creased to the extent that responses to 1 mM ACh were 
not significantly different from the pretreatment 300-µM 
control responses at the P < 0.05 level. One possible 
explanation is that 7 receptors with one or two func-
tional binding sites may be less affected by the rapid 
concentration-dependent desensitization that is charac-
teristic of 7 and, therefore, better able to respond to 
high concentrations of agonist.
Effects of ACh-insensitive mutant ratios in mixed 7  
wild-type/mutant heteromers
We have reported (Horenstein et al., 2007) a mutation 
in the primary face of the 7 ACh binding site (Y188F) 
that produces a 45-fold reduction in ACh potency (ACh 
EC50 shifted from 33 ± 4 µM for wild-type to 1,500 ±   
164 µM for 7Y188F) without any significant effect on the 
potency of the 7-selective partial agonist 4OH-GTS-21 
(4OH-GTS-21 EC50, 14 ± 1 µM for wild-type and 14 ± 2 µM 
for 7Y188F). As shown in Fig. 3 A, for wild-type 7, the 
ratio of the 300-µM 4OH-GTS-21–evoked net charge re-
sponses  to  300-µM  ACh-evoked  responses  was  0.57  ± 
0.04. In contrast, for 7Y188F receptors, the ratio of 
the 300-µM 4OH-GTS-21–evoked responses to 300-µM 
ACh-evoked responses was 4.0 ± 0.6. We coexpressed 
TA b L e   I
7L119C ratio experiments: net charge data after MTSEA treatment
a
mut/wt ratio Imax
b EC50
µM
1:1 1.16 ± 0.05 30 ± 4
3:1 0.83 ± 0.04 31 ± 4
5:1 0.78 ± 0.01 72 ± 3
aValues are the means ± SEM of at least five oocytes.
bMeasured relative to ACh maximum before MTSEA treatment.
Figure 3.  Probing for an 7 C-loop mutation with selective and 
nonselective  agonists.  (A)  Mutation  of  the  7  tyrosine  188  to   
phenylalanine reduces sensitivity to low concentrations of ACh, 
with little impact on sensitivity to the responses to the 7-selective 
agonist 4OH-GTS-21 (Horenstein et al., 2007). The upper traces 
are representative responses of oocytes expressing wild-type 7, 
for which 300 µM 4OH-GTS-21 evoked responses that are 57 ± 4%   
the magnitude of the responses evoked by 300 µM ACh, in net 
charge.  In  contrast,  for  oocytes  expressing  7Y188F,  300-µM 
4OH-GTS-21–evoked net charge responses that are 405 ± 55% 
of the magnitude of the responses evoked by 300 µM ACh.   
(B) Oocytes were injected with RNA for 7Y188F and wild-type 7 
at (mutant/wild-type) 1:0, 5:1, 3:1, 1:1, and 0:1 ratios and then 
tested for their relative responses to 300 µM ACh and 300 µM 
4OH-GTS-21. The values are plotted in relation to the fraction of 
7Y188F RNA injected at each ratio and are the means ± SEM of 
at least four oocytes for every condition.  Williams et al. 375
concentrations by >95% when the mutation homolo-
gous to 7L119C was placed in the 2 subunits of 42 
and 32 receptors, whereas little MTSEA-dependent 
effects  were  observed  when  the  homologous  muta-
tion was placed in the  subunits (Papke et al., 2011).   
Although the placement of the modifiable L119C residue 
in 7 receptors and the modifiable 2L121C in 42 
and 32 receptors impacts all potential binding sites 
of these receptors and produces equally profound re-
duction in function after MTSEA treatment, the effect 
of the homologous mutation in the subunits of hetero-
meric muscle-type receptors would be expected to de-
pend on the specific subunit(s) in which the mutation 
was placed because the 1 subunits are paired with dif-
ferent non– subunits ( and  or ), which contribute 
different complementary faces to the two agonist binding 
sites. Although MTSEA treatment produced no significant 
the wild-type receptor to ACh was retained well, even 
under the 5:1 injection condition, when it would be pre-
dicted that very few of the receptors would have more 
than one or two wild-type subunits. The shift in 4OH-
GTS-21 to ACh response ratios was no more than would 
have been expected from the prediction that 40% of 
receptors would contain only ACh-insensitive subunits.
Effects of mutations homologous to 7L119C  
in non– subunits of muscle-type receptors
Because structural modeling of the homomeric 7 sub-
units  places  the  L119  residue  in  the  complementary 
face of the agonist binding site (Fig. 1 A), this site is ex-
pected to form the specialized domains corresponding 
to those of the non– subunits in heteromeric nAChR. 
Consistent with this prediction, MTSEA treatment re-
duced responses to high (1-mM) and low (30-µM) ACh 
Figure 4.  The effect of MTSEA on 
muscle-type  receptors  with  muta-
tions  homologous  to  7L119C  in 
muscle  ,  ,  and    subunits.  Rep-
resentative  responses  obtained  be-
fore MTSEA treatments are shown as 
black lines, and responses obtained 
after MTSEA are shown as gray lines. 
The schematics to the right of the 
traces  represent  the  subunit  com-
position and disposition of the ACh 
binding sites for the different recep-
tor subtypes. The asterisks represent 
the location of the mutations in the 
complementary face of the agonist 
binding site.376 nAChR activation with single binding sites
current  responses  for  either  the  11L121C  or 
11L119C receptors. Although peak current re-
sponses to 1 mM ACh for the 11L121C receptors 
were decreased by MTSEA treatment (P < 0.01), the 
effect on 1-mM ACh responses (30 ± 7% decrease) was 
much less (P < 0.0001) than that on 30-µM ACh responses 
(74 ± 4% decrease). Note that although the peak ampli-
tude of the responses evoked from 11L121C and 
11L119C receptors by 1 mM was not decreased by 
the MTSEA treatment, the net charge values of the 1-mM 
ACh-evoked responses on all single-subunit mutants were 
affected because the MTSEA treatment resulted in cur-
rents with significantly (P < 0.05) faster 90–10% decay 
times. This would be consistent with a decreased ability 
of the treated oocytes to respond to the lower concentra-
tions of ACh during the washout period.
decreases  in  the  ACh-evoked  responses  of  wild-type 
11 or 11 receptors across a range of ACh con-
centrations from 1 µM to 1 mM (see Fig. 4 and Table II), 
receptors with mutations in both  and  had large 
reductions in their responses to both low and high 
concentrations of ACh (Fig. 4). Specifically, peak cur-
rent and net charge responses of the double mutants 
(11L119CL121C) to 30 µM ACh were reduced 93 ± 1 
and 96 ± 1%, respectively, and peak current and net 
charge responses to 1 mM ACh were reduced by 82 ± 6 
and 91 ± 3%, respectively. However, if mutations were 
placed in only one of the two non– subunits that contrib-
ute to agonist binding sites (11L121C, 11L119C, 
or 11L121C), MTSEA treatment produced large 
decreases (P < 0.01) in the responses evoked by 30 µM 
ACh, with less effect on the 1-mM ACh-evoked peak   
Figure  5.  ACh  concentration–
response  data  for  muscle-type 
single-subunit mutants before and   
after MTSEA treatment. Oocytes 
were stimulated alternately with 
control applications of 30 µM 
ACh and ACh at increasing con-
centrations: 1 µM, 10 µM, 100 µM, 
and 1 mM (i.e., the sequence of 
applications was 30, 1, 30, 10, 30, 
100, 30, 1,000, and 30). Next, the 
oocytes were treated with 2 mM 
MTSEA  for  60  s  before  being 
tested with the same sequence of 
ACh applications. All of the data 
were normalized to the individ-
ual oocytes’ average responses 
to the five 30-µM ACh applica-
tions  given  before  the  MTSEA 
treatment. Therefore, the 30-µM 
point in the pretreatment data   
is fixed at 1, and the SEM plot-
ted for that point is the average 
SEM of the five 30-µM responses 
obtained  from  each  cell.  The   
30-µM point in the post-MTSEA 
curve is based on the responses 
to 30 µM ACh obtained between 
the  posttreatment  10-µM  ACh 
and  100-µM  ACh  applications. 
The  plots  on  the  right  repre-
sent  the  repeated  30-µM  ACh 
responses obtained through the 
course of the entire experiments, 
normalized to the average pre-
MTSEA  30-µM  ACh  responses 
from each cell. The arrowhead 
indicates  the  point  at  which 
MTSEA was applied. The values 
plotted are the means ± SEM of 
five, three, and eight oocytes for 
11L121C,  11L119C, 
and 11L121C, respectively. 
Fit  parameters  are  listed  in   
Table II.  Williams et al. 377
receptors were 2.74 ± 0.05 pA and 2.70 ± 0.06 pA, re-
spectively. The single-channel amplitude with 10-nM ACh 
concentration at 70 mV was 3.13 ± 0.02 pA. The 
smaller apparent single-channel amplitude observed with 
high concentrations of ACh would be consistent with an 
effect of brief episodes of channel block by agonist, lim-
iting the detection of full amplitude events (Sine and 
Steinbach,  1984b).  The  single-channel  slope  conduc-
tance of 11L121C receptors was 35.5 ± 1.2 pS, and 
the  reversal  potential  was  4.4  ±  2.0  mV  (80  to   
80 mV; n = 3; not depicted). These values are in agree-
ment with previously published studies on fetal muscle-
type nAChR (Mishina et al., 1986; Schuetze and Role, 
1987; Jaramillo and Schuetze, 1988).
Fig. 6 A shows traces from outside-out patches under 
the experimental protocol, which consisted of an 80-s 
initial ACh application, followed by either 5 mM MTSEA 
or  external  saline  application  for  60  s,  and  ended 
with a follow-up ACh application. External saline in-
stead of 5 mM MTSEA was applied to some patches ex-
pressing  11L121C  to  allow  channel  rundown 
and/or desensitization that may occur independently 
of any MTSEA-dependent effects to be measured. Fig. 6 B 
summarizes  the  post-MTSEA  treatment  versus  pre- 
MTSEA comparisons  of  both  transient  peak  currents 
and NPopen with 1 mM ACh, normalized to the average 
values  from  eight  rundown/desensitization  control 
patches. Despite consistent experimental setup, the 
patch-to-patch variability of the peak current and NPopen 
measurements was higher than expected for unknown 
reasons that probably refﾭlﾭect the unstable and fragile 
nature of outside-out patches. No attempt was made to 
identify or eliminate outliers. There were no correla-
tions between post-/pre-MTSEA treatment peak and 
NPopen measurements and transfection dates, recording 
dates, lower limit of N in the patch, single-channel am-
plitudes, or 10–90% rise times. The non-normalized av-
erage, standard error, range, and median of values from 
at least eight replicates of each condition, including the 
rundown controls, are reported in Table III. Peak and 
NPopen measurements of wild-type receptors were least 
affected by MTSEA treatment (5 mM for 60 s), with 
post-/pre-MTSEA treatment values of 1.1 ± 0.1 and 
The ACh concentration–response curves for the peak 
current responses of the muscle-type receptors contain-
ing MTSEA-sensitive mutations are shown in Fig. 5, and 
the fit Imax and EC50 values are shown in Table II. In ad-
dition to obtaining responses to varying concentrations 
of ACh, multiple responses to ACh at the control con-
centration of 30 µM were obtained from each cell be-
fore and after MTSEA. These are shown in the right-hand 
column of plots in Fig. 5. Note that there was some re-
covery in the size of the 30-µM control responses after 
the MTSEA treatments. Given that the MTSEA modifi-
cation results in a covalent bond, reversibility of the effect 
seems unlikely. The response reversibility could have 
represented the insertion of new receptors during the 
course of the experiment. Muscle-type receptors express 
better than any other nAChR subtype, and oocytes must 
be studied immediately on the day after injection or 
else currents are too large for effective voltage clamping. 
Another possibility is that the receptors with one unmodi-
fied binding site show less of an effect of progressive de-
sensitization with repeated agonist applications.
To further investigate the MTSEA-resistant activation 
of muscle-type receptors with one unperturbed binding 
site, we performed single-channel patch clamp experi-
ments with wild-type and mutant 11 receptors 
transiently transfected in mammalian BOSC 23 cells. 
We focused on 11L121C because the fetal receptor 
is the subject of extensive literature as a result of its 
expression in BC3H1 cells (see for example, Sine and 
Steinbach, 1984a,b, 1987; Papke et al., 1988; Papke and 
Oswald, 1989). Two main types of analyses were per-
formed on the single-channel data: (1) comparison of 
post-MTSEA treatment peak current and NPopen mea-
surements with the pre-MTSEA measurements obtained 
from the same patch in response to 1 mM ACh; and   
(2) fitting of burst-duration histograms from untreated 
and treated receptors.
At a holding potential of 70 mV, the single-channel 
amplitudes before and after MTSEA treatment (5 mM for 
60 s) of wild-type receptors were 2.71 ± 0.02 pA and 
2.69 ± 0.01 pA, respectively, of 11L121C-mutant re-
ceptors were 2.64 ± 0.05 pA and 2.63 ± 0.03 pA, re-
spectively,  and  of  11L119CL121C  double-mutant 
TA b L e   I I
MTSEA effects on muscle mutants expressed in Xenopus oocytes
Muscle mutant Before MTSEA After MTSEA
Imax
a EC50 Imax
a EC50
µM µM
11L121C (n = 5) 1.30 ± 0.05 12.7 ± 1.5 1.41 ± 0.03 111 ± 8
11L119C (n = 3) 2.72 ± 0.08 48 ± 4 2.40 ± 0.02 126 ± 4
11L121C (n = 8) 2.56 ± 0.01 39.1 ± 0.4 1.84 ± 0.04 145 ± 9
11 wild-type (n = 5) 1.15 ± 0.03 4.52 ± 0.39 1.35 ± 0.05 3.24 ± 0.41
11 wild-type (n = 7) 1.28 ± 0.003 16.1 ± 0.10 1.53 ± 0.004 22.0 ± 0.11
aMeasured relative to average 30-µM ACh control before MTSEA treatment.378 nAChR activation with single binding sites
condition. The fit time constants are listed in Table IV. 
Burst durations, rather than apparent open duration 
histograms, are shown because open channel times are 
greatly affected by bandwidth limitations, such as missed 
brief closed intervals and ambiguities associated with 
idealization, whereas burst durations are much less 
affected by these potential confounders and are, there-
fore, a more reliable measure of channel opening   
behavior. The burst durations of wild-type 11 re-
ceptors were unaffected by MTSEA treatment, whereas 
the burst durations of 11L121C receptors were not 
different  from  wild-type  receptors  until  treated  with 
MTSEA. The number of components required to gener-
ate the best fit of the 11L121C burst-duration his-
togram after MTSEA increased from two to three, and 
most bursts consisted of brief, isolated openings, but 
some longer bursts remained. The proportion of total 
bursts of duration less than 2 ms increased from 0.26 ± 
0.04 before MTSEA treatment to 0.81 ± 0.03 after MTSEA 
treatment. The longest time constant after MTSEA treat-
ment was equivalent to the long time constant measured 
on nontreated patches (12.6 ± 0.2 ms vs. 12.9 ± 0.05 ms). 
The frequency (bursts/s) of bursts appeared to increase 
after MTSEA treatment by a factor of 2.78 ± 0.52 (1.88 ± 
0.35 without correction for rundown). Recordings from 
L121 mutants were also obtained without MTSEA 
treatment at low ACh concentrations (10 nM), where 
many of the observed openings were likely to arise from 
singly occupied receptors (Colquhoun and Sakmann, 
1981, 1985). The proportion of bursts corresponding to 
the brief time constant (0.26 ± 0.07 ms) was 0.43 ± 0.02, 
and the long time constant at 10 nM ACh was more brief 
than the long time constant at 1 mM ACh (4.66 ± 0.04 ms 
vs. 12.9 ± 0.05 ms).
D I S C U S S I O N
Other studies have investigated the relationship between 
available binding sites and agonist-evoked responses in 
muscle-type receptors (Sine and Taylor, 1980; Jha and 
Auerbach, 2010) and in an 7/5-HT3 chimeric receptor 
(Rayes et al., 2009). Sine and Taylor (1980) estimated 
the fractional blockade of binding sites with -cobratoxin 
and then measured ion fﾭlﾭux in toxin-bound vesicles 
from BC3H1 cells (fetal receptor). The conclusion was 
that only receptors with two free agonist binding sites 
could be activated. However, Groebe et al. (1995) re-
ported that the application of 500 nM -conotoxin M1 
to BC3H1 cells almost completely inhibits agonist-evoked 
responses, even though the 500-nM concentration of   
-conotoxin M1 theoretically results in <3% occupation 
of the low-affinity binding site (-) by the toxin on the 
BC3H1 nAChR (Groebe et al., 1995). In addition, Hansen 
et al. (2005) solved crystal structures for three states in 
the agonist binding site of the ACh binding protein, 
one of which was not part of the minimal model for   
0.83 ± 0.09, respectively. Receptors with one MTSEA-
sensitive binding site had post-/pretreatment peak cur-
rent and NPopen values of 0.74 ± 0.08 and 0.65 ± 0.06, 
respectively. There was a much greater reduction in both 
peak and NPopen values when receptors contained two 
MTSEA-sensitive binding sites, with post-/pretreatment 
values of 0.072 ± 0.003 and 0.14 ± 0.02, respectively.
Fig. 7 presents single-channel currents obtained from 
wild-type and 11L121C receptors at 1 mM ACh 
before  and  after  MTSEA  treatment,  responses  from   
untreated 11L121C receptors at 10 nM ACh, and 
fit  burst–duration  histograms  corresponding  to  each 
Figure 6.  The effect of MTSEA treatment on peak and NPopen re-
sponses from receptors expressed in BOSC 23 cells. (A) Example 
traces of outside-out patches from each condition. A rapid (≤0.7-ms) 
drug application system was used to apply ACh and MTSEA. 
(B) Summary of the effect of MTSEA treatment (5 mM for 60 s) 
on peak current and NPopen responses to 1 mM ACh shown as the 
average of post-MTSEA measurements relative to the pre-MTSEA 
measurements of each patch. The measurements are normalized 
to the average peak current and NPopen responses from eight run-
down/desensitization control patches. Asterisks above the values 
for 11L119CL121C indicate statistical significance (P < 0.01) 
when compared with values from either 11L121C or wild-
type. See Table III for values.  Williams et al. 379
be identified. The conclusions of this study were that 
7/5-HT3 chimeric receptors activated partially when 
receptors contained fewer than three wild-type subunits 
or when the three wild-type subunits were located at ad-
jacent subunit interfaces. In addition, the authors con-
cluded that receptors with fewer wild-type binding sites 
experienced  less  desensitization  after  strong  stimula-
tion by ACh. Unfortunately, the 7/5-HT3 chimera is a 
“man-made” receptor with a much higher open proba-
bility than native 7 nAChR, and so it is unclear to what 
extent the conclusions of this study may be applied to 7. 
Although our approach is not without its own limita-
tions, it provides the significant strength over the loss-of-
function mutation approach that we can record responses 
from the same receptor population before and after 
binding site modification. Notwithstanding the Sine 
and Taylor (1980) experiments, the general consensus 
from early single-channel recordings of muscle-type recep-
tors (see below) and experiments using loss-of-function 
mutations suggests that a single-agonist binding site is 
sufficient to open the nAChR channel, but that open-
ings from a single binding site have a low Popen relative 
to that of openings arising from multiple binding sites. 
Our results are not inconsistent with this observation, 
given that responses to ACh were reduced at low con-
centrations after binding site modification.
Early  single-channel  studies  of  muscle-type  nAChR 
noted that the component of brief openings at low agonist 
concentrations behaved as if it arose from mono-liganded 
receptors. The ratio of total events corresponding to 
the nAChR (closed, open, and desensitized states). This 
state was induced by the binding of -cobratoxin, but 
not by the binding of small competitive antagonists like 
methyllycaconitine. In this state, the C-loop extended in 
the opposite direction from which it presumably moves 
during the activation process (Hansen et al., 2005). There-
fore, it is possible that in the original Sine and Taylor 
(1980) experiments, the large conformational change 
produced by the binding of just one -cobratoxin mole-
cule was sufficient to render the entire channel unable 
to gate. Jha and Auerbach (2010) used mutations at po-
sition  W149  in  adult  receptors  to  produce  binding 
sites with reduced sensitivity to ACh, with the conclu-
sions being that a single agonist binding site can acti-
vate the receptor, but with much less efficiency than two 
binding sites (equilibrium gating constants: E1
ACh   
4.3 × 10
3 vs. E2
ACh  28). However, although expression of 
W149 mutant subunits resulted in receptors with two 
mutant binding sites and greatly reduced responses to 
ACh, the coexpression of W149-mutant subunits with 
wild-type  subunits to produce receptors with single 
functional binding sites resulted in mixed populations 
of receptors consisting of all wild-type subunits, single 
W149-mutant subunits, and two W149-mutant sub-
units. Rayes et al. (2009) used an 7/5-HT3 receptor 
chimera  with  subunits  containing  7Y190T  and/or 
7W55T mutations to reduce ACh sensitivity. In addi-
tion, the mutant subunits contained reporter mutations 
in the 5-HT3 sequence that altered unitary channel con-
ductance so that receptor subunit combinations could 
TA b L e   I I I
Peak current and NPopen measurements from the outside-out patch clamp experiments
a
Statistic 11L121C (control) (n = 8) 11L121C (n = 12) 11L119CL121C (n = 9) 11 (n = 8)
Average post-/pre- NPopen
b 0.44 (1) 0.28 (0.65) 0.060 (0.14) 0.36 (0.83)
SEM 0.13 0.059 0.015 0.085
Range 0.078–1.13 0.066–0.69 0.0088–0.11 0.14–0.65
Median 0.38 0.25 0.066 0.36
Average post-/pre- peak
b 0.41 (1) 0.31 (0.74) 0.030 (0.073) 0.44 (1.06)
SEM 0.081 0.084 0.0027 0.11
Range 0.11–0.74 0.051–1.10 0.020–0.045 0.14–0.78
Median 0.42 0.23 0.026 0.44
a1 mM ACh applied before and after 5-mM MTSEA treatment.
bNormalized NPopen and peak values are indicated in parentheses.
TA b L e   I V
Fit time constants from the burst-duration histograms
a
Receptor; condition 1 ± SEM P1 ± SEM 2 ± SEM P2 ± SEM 3 ± SEM P3 ± SEM
11; 1 mM ACh 0.15 ± 0.17 0.24 ± 0.03 12.2 ± 0.04 0.76 ± 0.02 — —
11 after MTSEA; 1 mM ACh 0.18 ± 0.15 0.26 ± 0.03 13.3 ± 0.04 0.74 ± 0.02 — —
11L121C; 1 mM ACh 0.13 ± 0.2 0.26 ± 0.04 12.9 ± 0.05 0.74 ± 0.02 — —
11L121C after MTSEA; 1 mM ACh 0.18 ± 0.08 0.47 ± 0.02 2.02 ± 0.12 0.34 ± 0.03 12.6 ± 0.2 0.19 ± 0.03
11L121C; 10 nM ACh 0.26 ± 0.07 0.43 ± 0.02 4.66 ± 0.04 0.57 ± 0.02 — —
a values indicated in milliseconds, and p-values indicate the fraction of total events estimated from histogram fit.380 nAChR activation with single binding sites
Interestingly, however, a component of short-lived open-
ings  persisted  even  at  high  agonist  concentrations,   
accounting for 10% of all apparent channel openings 
(Colquhoun and Sakmann, 1985; Jaramillo and Schuetze, 
1988). Before performing the patch clamp experiments, 
we  hypothesized  that  only  brief,  isolated  openings 
would be observed after MTSEA treatment of L121C 
brief, isolated openings (fast time constant) versus   
longer-lived openings (slow time constant) that were at-
tributed to di-liganded receptors was relatively high at low 
agonist concentrations, but decreased as agonist con-
centrations increased (Colquhoun and Sakmann, 1981, 
1985; Takeda and Trautmann, 1984; Labarca et al., 1985; 
Jaramillo and Schuetze, 1988; Papke and Oswald, 1989). 
Figure 7.  Single-channel traces 
and  fit  burst–duration  histo-
grams  from  wild-type  11 
and 11L121C receptors be-
fore and after MTSEA treatment   
(5  mM  for  60  s)  as  indicated. 
Bursts  from  11L121C  re-
ceptors before and after MTSEA 
treatment (indicated by * or #) 
are shown on the bottom row in 
higher time resolution together 
with  the  closed-duration  histo-
gram from 11L121C (before 
MTSEA treatment) used to de-
fine bursts. Currents were sam-
pled at 100 kHz and ultimately 
low-pass filtered to 5 kHz. Each 
histogram  represents  the  data 
pooled from at least individual 
four  patches  recorded  under 
identical conditions, except for   
the  10-nM  ACh  concentration   
histogram,  where  data  were 
pooled from three patches. Fit 
parameters are listed in Table IV.  Williams et al. 381
methyl groups for hydrogens on the quaternary nitrogen 
of the sulfhydryl reagent, the model for MTSEA-modified 
receptors is expected to be equivalent (Papke et al., 
2011). From these observations, and given that ACh con-
tains a positively charged ammonium group, it seems 
most likely that the residual current by the double mu-
tants was a result of a small fraction of incompletely 
modified receptors. Could the modification have spared 
some or all of the binding site affinity for ACh, primarily 
affecting the ability of the binding site to initiate the gat-
ing cascade once ACh bound? Protocols using 7C116S/
L119C mutants, MTSEA, and the positive allosteric mod-
ulator  N-(5-chloro-2,4-dimethoxy  phenyl)-N-(5-methyl-
3-isoxazolyl)-urea (PNU-120596), which converts some 
desensitized states into conducting states, suggest that 
MTSEA modification may stabilize mutant 7 receptors 
in PNU-120596–sensitive desensitized states because the 
application of PNU-120596 alone after MTSEA modifica-
tion produces activation. Importantly, MTSEA-modified 
receptors remain insensitive to ACh, even after they have 
been primed by the powerful allosteric modulator PNU-
120596 (Wang et al., 2010). In addition, the conversion 
of MTSEA-modified 7L119C-mutant receptors into the 
PNU-sensitive desensitized state only occurs when all 
five subunits contain the L119C mutation (unpublished 
data), suggesting that even though other binding sites 
may be in a desensitized state as a result of MTSEA modi-
fication, the receptor retains functionality with one or 
two unperturbed binding sites. However, although the 
receptor modeling and data favor the position that ACh 
is excluded from the ligand binding site, the modifica-
tion by MTSEA could conceivably mimic a permanently 
bound weak partial agonist, potentially increasing the 
ability of the unmodified binding site(s) to activate more 
readily upon binding of the full agonist ACh.
Because the proportion of the total synaptic cur-
rent from mono-liganded muscle-type receptors under 
normal physiological conditions is likely negligible, our 
data are arguably most interesting in their possible ap-
plication to neuronal nAChRs in the brain, where evi-
dence for nicotinic synaptic transmission is slim and 
agonist concentrations are expected to be low. In fact, 
some have wondered whether nAChRs in the brain even 
see  ACh  at  all  (Sivilotti  and  Colquhoun,  1995).  Our 
data show that Xenopus oocytes injected with a high per-
centage of 7L119C-mutant RNA, and therefore likely 
to have a reduced number of available agonist binding 
sites after MTSEA treatments, can give responses to 
high  agonist  concentrations  after  MTSEA  treatment 
that are comparable to the responses of receptors with 
all binding sites intact obtained at lower concentra-
tions of agonist. Likewise, combinations of wild-type and 
7Y188F receptors likely to have very few ACh-sensitive 
wild-type subunits nonetheless respond well to ACh.
If submaximal occupancy by agonist is sufficient to 
activate heteromeric and homomeric receptors, what is 
receptors, with the frequency of such events increasing 
as agonist concentration increased. The majority (81%) 
of bursts were indeed brief (≤2 ms); however, some lon-
ger bursts (12.6 ms) were also observed. This observa-
tion, together with previous observations that brief, 
isolated single-channel openings persist at high agonist 
concentrations (Colquhoun and Sakmann, 1985), sug-
gests the interesting possibility that both short- and 
longer-lived channel activations may arise from either 
mono- or di-liganded receptors, with a single-liganded 
binding site opening with greatest probability to the 
shorter-lived opening, and the di-liganded receptor open-
ing to the longer-lived open state with greater probabil-
ity. In general, our data support the interpretation that 
conversion to the desensitized state occurs as in relation 
to the total time spent in the open state. Individual 
openings  from  singly  liganded  receptors  may  with 
higher likelihood be brief; nonetheless, if entry into de-
sensitized states depends strictly on time in the open state, 
such receptors would generate the same net amount of 
current before desensitizing as di-liganded receptors. 
This hypothesis, that entry of receptors into the desen-
sitized state depends strictly on time in the open state,   
is consistent with classical Markov models used to de-
scribe ion channel behavior (Katz and Thesleff, 1957; 
Sakmann et al., 1985; Sine and Steinbach, 1986).
Ideally, MTSEA modification occurred to completion 
at all “L119C” sites, producing binding sites with no 
affinity for ACh, and with no effect on channel gating 
itself. The observation that some currents were recorded 
after  MTSEA  was  applied  to  the  11L121CL119C 
double  mutants  in  both  two-electrode  voltage  clamp 
and patch clamp experiments is problematic. Does the 
MTSEA modification only partially reduce the binding 
site sensitivity to ACh, or were some receptors left unmodi-
fied? Unfortunately, neither question is straightforward 
to answer. In a study evaluating residues that contribute 
to -btx binding in muscle-type receptors, Sine (1997) 
demonstrated that [2-(trimethylammonium)ethyl] meth-
anethiosulfonate (MTSET) modification of receptors 
containing  L121C,  L119C,  or  L119C  residues   
resulted in a 50% decrease in -btx binding, as would be 
expected if the receptors contained only one modified 
binding site and modification completely prevented   
-btx binding. Furthermore, analysis of the binding 
site–selective  antagonists  dimethyl-d-tubocurarine  and 
-conotoxin M1 confirmed that the effect was a result of 
specific modification at the selected binding site. Elec-
trostatic repulsion, rather than effects on channel con-
formation, was hypothesized to be responsible for the 
disruption of -btx binding after MTSET modification 
(Sine, 1997). In addition, a recently constructed homol-
ogy model of MTSET-modified 7L119C suggests that 
the modification places a hard positive charge in close 
proximity to where ACh is expected to bind. Because 
MTSET differs from MTSEA only in the substitution of 382 nAChR activation with single binding sites
activation, based on partial occupancy of the multiple 
binding sites, may be an important functional modality 
mediating the cyto-protective and perhaps also the cogni-
tive effects documented for 7-selective agonists.
We thank Lisa Jacobs, Jenny Hughes, Chad Brodbeck, Ke Ren, 
and Sara Braley for technical assistance. We thank Drs. Edwin 
Meyer,  Robert  Oswald,  Joe  Henry  Steinbach,  Stephen  Baker,   
Jan Torleif Pedersen, and Jan Egebjerg for helpful comments, and 
Dr. Steven Sine for providing the wild-type muscle receptor cDNAs 
subcloned in pRBG4.
This  work  was  supported  by  National  Institutes  of  Health 
grants RO1-GM057481 and T32-AG000196.
Angus C. Nairn served as editor.
Submitted: 15 December 2010
Accepted: 17 February 2011
R E F E R E N C E S
Amin, J., and D.S. Weiss. 1996. Insights into the activation mech-
anism  of  rho1  GABA  receptors  obtained  by  coexpression 
of  wild  type  and  activation-impaired  subunits.  Proc.  Biol.  Sci.  
263:273–282. doi:10.1098/rspb.1996.0042
Barron,  S.C.,  J.T.  McLaughlin,  J.A.  See,  V.L.  Richards,  and  R.L. 
Rosenberg.  2009.  An  allosteric  modulator  of  alpha7  nicotinic 
receptors,  N-(5-Chloro-2,4-dimethoxyphenyl)-N’-(5-methyl-3-
isoxazolyl)-urea (PNU-120596), causes conformational changes 
in the extracellular ligand binding domain similar to those 
caused by acetylcholine. Mol. Pharmacol. 76:253–263. doi:10.1124/ 
mol.109.056226
Beato, M., P.J. Groot-Kormelink, D. Colquhoun, and L.G. Sivilotti. 
2004. The activation mechanism of alpha1 homomeric glycine re-
ceptors. J. Neurosci. 24:895–906. doi:10.1523/JNEUROSCI.4420- 
03.2004
Brejc, K., W.J. van Dijk, R.V. Klaassen, M. Schuurmans, J. van Der 
Oost, A.B. Smit, and T.K. Sixma. 2001. Crystal structure of an 
Ach-binding protein reveals the ligand-binding domain of nico-
tinic receptors. Nature. 411:269–276.
Celie, P.H., S.E. van Rossum-Fikkert, W.J. van Dijk, K. Brejc, A.B. Smit, 
and T.K. Sixma. 2004. Nicotine and carbamylcholine binding to 
nicotinic acetylcholine receptors as studied in AChBP crystal struc-
tures. Neuron. 41:907–914. doi:10.1016/S0896-6273(04)00115-1
Colquhoun, D., and B. Sakmann. 1981. Fluctuations in the micro-
second time range of the current through single acetylcholine re-
ceptor ion channels. Nature. 294:464–466. doi:10.1038/294464a0
Colquhoun, D., and B. Sakmann. 1985. Fast events in single-chan-
nel currents activated by acetylcholine and its analogues at the 
frog muscle end-plate. J. Physiol. 369:501–557.
Colquhoun, D., and B. Sakmann. 1995. Fitting and statistical analysis of 
single-channel records. In Single-Channel Recording. B. Sakmann 
and E. Neher, editors. Plenum Press, New York. 483–585.
Dani, J.A., and D. Bertrand. 2007. Nicotinic acetylcholine recep-
tors and nicotinic cholinergic mechanisms of the central nervous   
system. Annu. Rev. Pharmacol. Toxicol. 47:699–729. doi:10.1146/ 
annurev.pharmtox.47.120505.105214
de Jonge, W.J., and L. Ulloa. 2007. The alpha7 nicotinic acetylcho-
line receptor as a pharmacological target for infﾭlﾭammation. Br.   
J. Pharmacol. 151:915–929. doi:10.1038/sj.bjp.0707264
Descarries,  L.,  V.  Gisiger,  and  M.  Steriade.  1997.  Diffuse  trans-
mission  by  acetylcholine  in  the  CNS.  Prog.  Neurobiol.  53:603– 
625. doi:10.1016/S0301-0082(97)00050-6
Franke, C., H. Hatt, and J. Dudel. 1987. Liquid filament switch 
for  ultra-fast  exchanges  of  solutions  at  excised  patches  of 
the role of the additional binding sites? Especially in the 
case of 7, the functional consequence of having multi-
ple ACh binding sites may be sensitivity to low levels of 
agonist rather than to require high levels of occupancy 
for activation. High levels of agonist occupancy only   
appear to promote desensitization, or at least to provide 
sufficient activation during the process of achieving 
high levels of agonist site occupancy for the receptors to 
become desensitized. When challenged with a high con-
centration of agonist, 7 receptors open with highest 
probability during the leading edge of the solution ex-
change, when only a fraction of the agonist binding 
sites would be occupied (Papke and Thinschmidt, 1998; 
Papke et al., 2000; Papke and Porter Papke, 2002; Uteshev 
et al., 2002, 2003), after which the receptors are pre-
dominantly closed or desensitized. This is true whether 
recordings are made on a slow time scale in oocytes 
(Papke and Thinschmidt, 1998) or on a rapid time scale 
with dissociated neurons (Uteshev et al., 2002), and this 
is so pronounced that with our normal experimental 
protocol, the time-integrated (i.e., net charge) response 
to 3 mM ACh shows no significant increase over that 
evoked by 100 µM ACh. The rapid desensitization of 
7 may be a protective mechanism against cytotoxicity 
induced by excess entry of calcium. We also hypothesize 
that although the desensitized state is nonconducting, 
channel desensitization itself may provide another di-
mension of neuronal nAChR-mediated transduction of 
cellular signals (Suzuki et al., 2006; de Jonge and Ulloa, 
2007) of particular importance for 7.
The nature of the desensitized state appears to be 
rather different for heteromeric and homomeric recep-
tors. For heteromeric receptors, desensitization is asso-
ciated with an approximately thousand-fold increase in 
the apparent affinity of the agonist binding site for ACh, 
whereas in 7 receptors there does not appear to be any 
more than a 10-fold increase in agonist affinity with   
desensitization (Uteshev et al., 2002). The conversion of 
heteromeric receptors to a high-affinity desensitized state 
means they will be likely to retain agonist at the binding 
sites or rebind agonist even as agonist concentration de-
creases. This may have the effect of stabilizing the desen-
sitized state and slowing recovery. In contrast, agonist will 
readily dissociate from homomeric 7 receptors, so that 
in the presence of low concentrations of agonist, the re-
ceptors may easily cycle between activation and desensiti-
zation, and generate a significant time-integrated calcium 
signal over a prolonged period of time. This modality of 
prolonged stimulation by low levels of agonist has been 
shown to be what is required to achieve cyto-protective 
effects via 7 receptors (Li et al., 1999) and is probably 
important for other roles played by 7 receptors in the 
brain (Uteshev et al., 2002) and in non-neuronal tissues 
(Wang et al., 2003). Therefore, because it is likely that   
in vivo 7 receptors are tonically exposed to low level stim-
ulation (via choline and diffuse release of ACh), receptor   Williams et al. 383
depends on subunit occupancy. J. Physiol. 535:427–443. doi:10.1111/ 
j.1469-7793.2001.00427.x
Numa,  S.,  M.  Noda,  H.  Takahashi,  T.  Tanabe,  M.  Toyosato,  Y. 
Furutani, and S. Kikyotani. 1983. Molecular structure of the nico-
tinic acetylcholine receptor. Cold Spring Harb. Symp. Quant. Biol. 
48:57–69.
Palma, E., S. Bertrand, T. Binzoni, and D. Bertrand. 1996. Neuronal 
nicotinic alpha 7 receptor expressed in Xenopus oocytes pres-
ents five putative binding sites for methyllycaconitine. J. Physiol. 
491:151–161.
Papke, R.L., and R.E. Oswald. 1989. Mechanisms of noncompeti-
tive inhibition of acetylcholine-induced single-channel currents. 
J. Gen. Physiol. 93:785–811. doi:10.1085/jgp.93.5.785
Papke, R.L., and J.K. Porter Papke. 2002. Comparative pharmacol-
ogy of rat and human alpha7 nAChR conducted with net charge 
analysis. Br. J. Pharmacol. 137:49–61. doi:10.1038/sj.bjp.0704833
Papke, R.L., and J.S. Thinschmidt. 1998. The correction of alpha7 
nicotinic acetylcholine receptor concentration-response rela-
tionships in Xenopus oocytes. Neurosci. Lett. 256:163–166. doi:10 
.1016/S0304-3940(98)00786-1
Papke, R.L., G. Millhauser, Z. Lieberman, and R.E. Oswald. 1988. 
Relationships  of  agonist  properties  to  the  single  channel  ki-
netics  of  nicotinic  acetylcholine  receptors.  Biophys.  J.  53:1–10.   
doi:10.1016/S0006-3495(88)83059-5
Papke, R.L., M. Bencherif, and P. Lippiello. 1996. An evaluation 
of neuronal nicotinic acetylcholine receptor activation by quater-
nary nitrogen compounds indicates that choline is selective for 
the  7 subtype. Neurosci. Lett. 213:201–204.
Papke, R.L., E. Meyer, T. Nutter, and V.V. Uteshev. 2000. alpha7 
receptor-selective agonists and modes of alpha7 receptor ac-
tivation.  Eur.  J.  Pharmacol.  393:179–195.  doi:10.1016/S0014- 
2999(00)00009-1
Papke, R.L., C. Stokes, D.K. Williams, J. Wang, and N.A. Horenstein. 
2011. Cysteine accessibility analysis of the human alpha7 nicotinic 
acetylcholine  receptor  ligand-binding  domain  identifies  L119   
as a gatekeeper. Neuropharmacology. 60:159–171. doi:10.1016/ 
j.neuropharm.2010.07.014
Press,  W.H.  1988.  Numerical  Recipes  in  C:  The  Art  of  Scientific 
Computing. Cambridge University Press, Cambridge, UK. 768 pp.
Rayes, D., M.J. De Rosa, S.M. Sine, and C. Bouzat. 2009. Number 
and  locations  of  agonist  binding  sites  required  to  activate   
homomeric  Cys-loop  receptors.  J.  Neurosci.  29:6022–6032.  doi: 
10.1523/JNEUROSCI.0627-09.2009
Sakmann, B., C. Methfessel, M. Mishina, T. Takahashi, T. Takai, M. 
Kurasaki, K. Fukuda, and S. Numa. 1985. Role of acetylcholine 
receptor  subunits  in  gating  of  the  channel.  Nature.  318:538– 
543. doi:10.1038/318538a0
Schuetze, S.M., and L.W. Role. 1987. Developmental regulation of 
nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 10:403–457. 
doi:10.1146/annurev.ne.10.030187.002155
Scremin, O.U., and D.J. Jenden. 1991. Time-dependent changes in 
cerebral choline and acetylcholine induced by transient global 
ischemia in rats. Stroke. 22:643–647.
Sine, S.M. 1997. Identification of equivalent residues in the gamma, 
delta, and epsilon subunits of the nicotinic receptor that con-
tribute to alpha-bungarotoxin binding. J. Biol. Chem. 272:23521–
23527. doi:10.1074/jbc.272.38.23521
Sine, S.M. 2002. The nicotinic receptor ligand binding domain.   
J. Neurobiol. 53:431–446. doi:10.1002/neu.10139
Sine,  S.M.,  and  J.H.  Steinbach.  1984a.  Activation  of  a  nicotinic   
acetylcholine receptor. Biophys. J. 45:175–185. doi:10.1016/S0006- 
3495(84)84146-6
Sine,  S.M.,  and  J.H.  Steinbach.  1984b.  Agonists  block  currents 
through  acetylcholine  receptor  channels.  Biophys.  J.  46:277– 
283. doi:10.1016/S0006-3495(84)84022-9
synaptic  membrane  of  crayfish  muscle.  Neurosci.  Lett.  77:199– 
204. doi:10.1016/0304-3940(87)90586-6
Groebe,  D.R.,  J.M.  Dumm,  E.S.  Levitan,  and  S.N.  Abramson. 
1995. alpha-Conotoxins selectively inhibit one of the two ace-
tylcholine binding sites of nicotinic receptors. Mol. Pharmacol. 
48:105–111.
Guex, N., and M.C. Peitsch. 1997. SWISS-MODEL and the Swiss-
PdbViewer: an environment for comparative protein modeling. 
Electrophoresis. 18:2714–2723. doi:10.1002/elps.1150181505
Hansen,  S.B.,  G.  Sulzenbacher,  T.  Huxford,  P.  Marchot,  P. 
Taylor,  and  Y.  Bourne.  2005.  Structures  of  Aplysia  AChBP 
complexes  with  nicotinic  agonists  and  antagonists  reveal  dis-
tinctive binding interfaces and conformations. EMBO J. 24:3635– 
3646. doi:10.1038/sj.emboj.7600828
Horenstein,  N.A.,  T.J.  McCormack,  C.  Stokes,  K.  Ren,  and  R.L. 
Papke. 2007. Reversal of agonist selectivity by mutations of con-
served  amino  acids  in  the  binding  site  of  nicotinic  acetylcho-
line receptors. J. Biol. Chem. 282:5899–5909. doi:10.1074/jbc 
.M609202200
Jackson,  M.B.  1984.  Spontaneous  openings  of  the  acetylcholine 
receptor  channel.  Proc.  Natl.  Acad.  Sci.  USA.  81:3901–3904.   
doi:10.1073/pnas.81.12.3901
Jackson,  M.B.  1986.  Kinetics  of  unliganded  acetylcholine  recep-
tor channel gating. Biophys. J. 49:663–672. doi:10.1016/S0006- 
3495(86)83693-1
Jackson, M.B. 1998. Single-channel recording. Curr. Protoc. Neurosci. 
6.8:1–32.
Jaramillo, F., and S.M. Schuetze. 1988. Kinetic differences between 
embryonic-  and  adult-type  acetylcholine  receptors  in  rat  myo-
tubes. J. Physiol. 396:267–296.
Jha,  A.,  and  A.  Auerbach.  2010.  Acetylcholine  receptor  chan-
nels activated by a single agonist molecule. Biophys. J. 98:1840– 
1846. doi:10.1016/j.bpj.2010.01.025
Jonas, P. 1995. Fast application of agonists to isolated membrane 
patches. In Single-Channel Recording. B. Sakmann and E. Neher, 
editors. Plenum Press, New York. 231–243.
Jope, R.S., and X. Gu. 1991. Seizures increase acetylcholine and 
choline  concentrations  in  rat  brain  regions.  Neurochem.  Res. 
16:1219–1226. doi:10.1007/BF00966699
Kabakov, A.Y., and R.L. Papke. 1998. Ultra fast solution applications 
for prolonged gap-free recordings: controlling a Burleigh piezo-
electric positioner with Clampex7. Axobits. January:6–9.
Karlin, A., and D.A. Cowburn. 1973. The affinity-labeling of par-
tially  purified  acetylcholine  receptor  from  electric  tissue  of 
Electrophorus.  Proc.  Natl.  Acad.  Sci.  USA.  70:3636–3640.  doi: 
10.1073/pnas.70.12.3636
Katz, B., and S. Thesleff. 1957. A study of the desensitization produced 
by acetylcholine at the motor end-plate. J. Physiol. 138:63–80.
Labarca, P., M.S. Montal, J.M. Lindstrom, and M. Montal. 1985. The 
occurrence of long openings in the purified cholinergic receptor 
channel increases with acetylcholine concentration. J. Neurosci. 
5:3409–3413.
Li,  Y.,  R.L.  Papke,  Y.-J.  He,  W.J.  Millard,  and  E.M.  Meyer.  1999. 
Characterization  of  the  neuroprotective  and  toxic  effects 
of  7  nicotinic  receptor  activation  in  PC12  cells.  Brain  Res.  
830:218–225. doi:10.1016/S0006-8993(99)01372-4
Mishina, M., T. Takai, K. Imoto, M. Noda, T. Takahashi, S. Numa, 
C.  Methfessel,  and  B.  Sakmann.  1986.  Molecular  distinction   
between fetal and adult forms of muscle acetylcholine receptor. 
Nature. 321:406–411. doi:10.1038/321406a0
Mortensen,  M.,  and  T.G.  Smart.  2007.  Single-channel  record-
ing of ligand-gated ion channels. Nat. Protoc. 2:2826–2841. doi: 
10.1038/nprot.2007.403
Mott, D.D., K. Erreger, T.G. Banke, and S.F. Traynelis. 2001. Open 
probability of homomeric murine 5-HT3A serotonin receptors   384 nAChR activation with single binding sites
cell activation toward a neuroprotective role. J. Neurosci. Res.  
83:1461–1470. doi:10.1002/jnr.20850
Takeda, K., and A. Trautmann. 1984. A patch-clamp study of the 
partial agonist actions of tubocurarine on rat myotubes. J. Physiol. 
349:353–374.
Uteshev, V.V., E.M. Meyer, and R.L. Papke. 2002. Activation and 
inhibition of native neuronal alpha-bungarotoxin-sensitive nico-
tinic  ACh  receptors.  Brain  Res.  948:33–46.  doi:10.1016/S0006- 
8993(02)02946-3
Uteshev, V.V., E.M. Meyer, and R.L. Papke. 2003. Regulation of neuro-
nal function by choline and 4OH-GTS-21 through alpha 7 nicotinic 
receptors. J. Neurophysiol. 89:1797–1806. doi:10.1152/jn.00943.2002
Wang, H., M. Yu, M. Ochani, C.A. Amella, M. Tanovic, S. Susarla, 
J.H. Li, H. Wang, H. Yang, L. Ulloa, et al. 2003. Nicotinic acetyl-
choline receptor alpha7 subunit is an essential regulator of in-
fﾭlﾭammation. Nature. 421:384–388. doi:10.1038/nature01339
Wang,  J.,  N.A.  Horenstein,  C.  Stokes,  and  R.L.  Papke.  2010. 
Tethered agonist analogs as site-specific probes for domains of 
the  human  7  nicotinic  acetylcholine  receptor  that  differen-
tially  regulate  activation  and  desensitization.  Mol.  Pharmacol.  
78:1012–1025. doi:10.1124/mol.110.066662
Sine, S.M., and J.H. Steinbach. 1986. Activation of acetylcholine re-
ceptors on clonal mammalian BC3H-1 cells by low concentrations   
of agonist. J. Physiol. 373:129–162.
Sine, S.M., and J.H. Steinbach. 1987. Activation of acetylcholine 
receptors on clonal mammalian BC3H-1 cells by high concentra-
tions of agonist. J. Physiol. 385:325–359.
Sine, S.M., and P. Taylor. 1980. The relationship between agonist 
occupation  and  the  permeability  response  of  the  cholinergic 
receptor  revealed  by  bound  cobra  alpha-toxin.  J.  Biol.  Chem. 
255:10144–10156.
Sivilotti,  L.,  and  D.  Colquhoun.  1995.  Acetylcholine  receptors: 
too  many  channels,  too  few  functions.  Science.  269:1681–1682. 
doi:10.1126/science.7569892
Stokes,  C.,  J.K.P.  Papke,  N.A.  Horenstein,  W.R.  Kem,  T.J. 
McCormack, and R.L. Papke. 2004. The structural basis for GTS-21   
selectivity  between  human  and  rat  nicotinic  alpha7  receptors. 
Mol. Pharmacol. 66:14–24. doi:10.1124/mol.66.1.14
Suzuki,  T.,  I.  Hide,  A.  Matsubara,  C.  Hama,  K.  Harada,  K. 
Miyano,  M.  Andrä,  H.  Matsubayashi,  N.  Sakai,  S.  Kohsaka, 
et  al.  2006.  Microglial  alpha7  nicotinic  acetylcholine  recep-
tors drive a phospholipase C/IP3 pathway and modulate the 